Case reports highlighted the potential efficacy of oral anti-angiogenic TKIs in the TET patient population, including a thymic carcinoma patient harboring a c-Kit missense mutation who responded to sorafenib and several patients who underwent receptor tyrosine kinase analysis that revealed activation in PDGFβ and VEGF3 and subsequently received sunitinib and experienced partial responses in three out of four patients with metastatic thymic carcinoma that was refractory to standard therapies [86,87]. This evidence concerns the gene NTRK1 and thymic carcinoma.